Status:
UNKNOWN
Cardiac Amyloidosis : Diagnostic Using Red Flag Signals
Lead Sponsor:
University Hospital Center of Martinique
Collaborating Sponsors:
Pfizer
Conditions:
Cardiac Amyloidosis
Eligibility:
All Genders
45+ years
Brief Summary
Cardiac amyloidosis is an increasingly contributor of degenerative cardiac diseases. However, its frequency remains underestimated, and diagnosis is often realized at late stages of the disease. A lar...
Detailed Description
The objective is to evaluate the clinical and epidemiological aspects of cardiac amyloidosis using a systematic screening of even moderate left ventricular hypertrophy, taking into account the presenc...
Eligibility Criteria
Inclusion
- Diagnosis of left ventricular hypertrophy defined by a parietal thickness (interventricular septum or posterior wall) ≥ 12 mm on the echocardiogram
- Age equal or greater than 45 years
- Current residency in Martinique, Guadeloupe or French Guyana
- Ability to receive and understand research information
- Ability to freely deliver informed written consent
Exclusion
- Pregnant or breastfeeding woman
- Severe uncontrolled hypertension
- Chronic hemodialysis
- Person under legal protection measures (guardianship, curatorship, safeguard of justice), and person deprived of liberty
Key Trial Info
Start Date :
September 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
424 Patients enrolled
Trial Details
Trial ID
NCT04459169
Start Date
September 30 2020
End Date
December 31 2021
Last Update
November 17 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de Basse-Terre
Basse-Terre, Guadeloupe, 97100
2
CHU de Martinique
Fort-de-France, Martinique, 97261
3
CHU de Martinique
La Trinité, Martinique, 97220